Perspective Therapeutics CATX
NYSE CATX
$2.75 +0.02 (+0.73%)
At close: Oct 2, 2026 · 4:00 PM EDT

Perspective Therapeutics (CATX) Gains from Sales and Divestitures (2016 - 2024)

Updated

Perspective Therapeutics' Gains from Sales and Divestitures was -$59,000 in FY2024, compared with -$4.17 million in FY2023.

Analysis

Perspective Therapeutics (CATX) Gains from Sales and Divestitures (2016 - 2024) Analysis & Trends

From FY2016 onward, Perspective Therapeutics has reported Gains from Sales and Divestitures for 7 years.

  • The FY2024 figure marks the highest annual Gains from Sales and Divestitures since FY2021.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was -$4.17 million in FY2023, -$305,000 in FY2022 and -$10,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Perspective Therapeutics 313.74 Mn 313.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 -59,000.00
Dec 31, 2023 -4.15 Mn
Mar 31, 2023 -22,000.00
Dec 31, 2022 -305,000.00
Mar 31, 2021 -3,000.00
Mar 31, 2019 1,000.00
Jun 30, 2017 7,000.00
Sep 30, 2016 -5,000.00
Mar 31, 2016 -7,000.00
API Access

Perspective Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CATX&period=max&api_key=YOUR_API_KEY